Daratumumab (re-assessment: multiple myeloma; ≥ 1 prior therapy; combination with lenalidomide and dexamethasone or bortezomib and dexamethasone)

Subject:

• Active Substance: Daratumumab
• Name: Darzalex^®
• Therapeutic area: Multiple myeloma
• Pharmaceutical company: Janssen-Cilag GmbH

Time table:

• Start: 01.04.2022
• Final decision by G-BA: 15.09.2022

Final decision:

• Proof for a considerable additional benefit